RayzeBio, Inc. Common Stock (RYZB) NASDAQ
$62.49 0.01 (0.02%)
Market Cap: $3.75B
As of 02/23/24 04:00 PM EST. Market closed.
RayzeBio, Inc. Common Stock (RYZB)
NASDAQ
$62.49
0.01 (0.02%)
Market Cap: $3.75B
As of 02/23/24 04:00 PM EST. Market closed.
Add to Portfolio
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Kenneth Song M.D.
Full Time Employees
88
URL
Address
.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Kenneth Song M.D.
Full Time Employees
88
URL
Address
.
PRICE CHART FOR RAYZEBIO, INC. COMMON STOCK
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$62.49
Previous Close
$62.48
Days Range
$62.48 - $62.50
52 week range
$17.95 - $62.51
Volume
282,719
Avg. Volume (30 days)
745,490
Market Cap
$3.75B
Dividend Yield
-
P/E
(57.86)
Shares Outstanding
60,016,400
Open
$62.49
Previous Close
$62.48
Days Range
$62.48 - $62.50
52 week range
$17.95 - $62.51
Volume
282,719
Avg. Volume (30 days)
745,490
Market Cap
$3.75B
Dividend Yield
-
P/E
(57.86)
Shares Outstanding
60,016,400
FINANCIAL STATEMENTS FOR RAYZEBIO, INC. COMMON STOCK
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR RAYZEBIO, INC. COMMON STOCK
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Heyman Richard A. | Director | Feb 26, 2024 | Option Exercise | $62.50 | 367,446 | 22,965,375 | 0 | Feb 27, 2024, 04:59 PM |
| Katabi Maha | Director | Feb 26, 2024 | Option Exercise | $62.50 | 2,419,528 | 151,220,500 | 0 | Feb 27, 2024, 04:47 PM |
| Moran Susan | CHIEF MEDICAL OFFICER | Feb 26, 2024 | Option Exercise | $62.50 | 323,455 | 20,215,938 | 0 | Feb 27, 2024, 04:45 PM |
| Kush Arvind | CHIEF FINANCIAL OFFICER | Feb 26, 2024 | Option Exercise | $62.50 | 78,433 | 4,902,063 | 0 | Feb 27, 2024, 04:42 PM |
| SONG KENNETH | PRESIDENT AND CHIEF EXECUTIVE | Feb 26, 2024 | Option Exercise | $62.50 | 1,622,968 | 101,435,500 | 0 | Feb 27, 2024, 04:41 PM |
| Moran Susan | CHIEF MEDICAL OFFICER | Jan 22, 2024 | Option Exercise | $3.24 | 30,875 | 100,035 | 322,647 | Feb 06, 2024, 06:11 PM |
| Katabi Maha | Director | Sep 19, 2023 | Buy | $18.00 | 472,222 | 8,499,996 | 1,209,764 | Sep 21, 2023, 05:10 PM |
| VIKING GLOBAL INVESTORS LP | 10% Owner | Sep 19, 2023 | Buy | $18.00 | 1,388,889 | 25,000,002 | 4,899,144 | Sep 21, 2023, 05:00 PM |
| VIKING GLOBAL INVESTORS LP | 10% Owner | Sep 19, 2023 | Buy | $18.00 | 1,388,889 | 25,000,002 | 4,899,144 | Sep 21, 2023, 04:59 PM |
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Heyman Richard A. | Director | 02/26/2024 | 22,965,375 |
| Katabi Maha | Director | 02/26/2024 | 151,220,500 |
| Moran Susan | CHIEF MEDICAL OFFICER | 02/26/2024 | 20,215,938 |
| Kush Arvind | CHIEF FINANCIAL OFFICER | 02/26/2024 | 4,902,063 |
| SONG KENNETH | PRESIDENT AND CHIEF EXECUTIVE | 02/26/2024 | 101,435,500 |
| Moran Susan | CHIEF MEDICAL OFFICER | 01/22/2024 | 100,035 |
| Katabi Maha | Director | 09/19/2023 | 8,499,996 |
| VIKING GLOBAL INVESTORS LP | 10% Owner | 09/19/2023 | 25,000,002 |
| VIKING GLOBAL INVESTORS LP | 10% Owner | 09/19/2023 | 25,000,002 |
BUYBACK ANNOUNCEMENT(S) FOR RAYZEBIO, INC. COMMON STOCK
LOADING...